AstraZeneca receives warning on Seroquel sales aid

Share this article:
The FDA asked AstraZeneca to halt distribution of a professional sales aid for its antipsychotic medication Seroquel. In a warning letter to AstraZeneca, the FDA’s Division of Drug Marketing, Advertising & Communications division wrote that the Seroquel sales aid is misleading because “it minimizes the risk of hyperglycemia and diabetes mellitus and fails to communicate important information regarding neuroleptic malignant syndrome, tardive dyskinesia and the bolded cataracts precaution.” Seroquel’s labeling says neuroleptic malignant syndrome, which can be fatal, has been reported in association of antipsychotic drugs, including Seroquel. AstraZeneca has until Nov. 30 to respond to the warning. Seroquel had global sales of $2.8 billion last year.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.